Multiple endocrine neoplasia type 1 screening

Multiple endocrine neoplasia type 1 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 1 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Multiple endocrine neoplasia type 1 screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple endocrine neoplasia type 1 screening
CDC on Multiple endocrine neoplasia type 1 screening
Multiple endocrine neoplasia type 1 screening in the news
Blogs on Multiple endocrine neoplasia type 1 screening
Directions to Hospitals Treating Multiple endocrine neoplasia type 1
Risk calculators and risk factors for Multiple endocrine neoplasia type 1 screening

Template:CMGG; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [1]

Screening

Screening and surveillance for MEN1 may employ a combination of biochemical tests and imaging. Available recommendations are summarized in the following table.

valign=top Biochemical Test or Procedure Condition Screened For Age Screening Initiated (y) Frequency Serum prolactin and/or insulin-like growth factor 1 Pituitary tumors 5 Every 1 y Fasting total serum calcium and/or ionized calcium and PTH Parathyroid tumors and PHPT 8 Every 1 y Fasting serum gastrin Duodenopancreatic gastrinoma 20 Every 1 y Chromogranin A, pancreatic polypeptide, glucagon, and vasointestinal polypeptide Pancreatic NETs <10years Every 1 y Fasting glucose and insulin Insulinoma 5 Every 1 y Brain MRI Pituitary tumors 5 Every 3–5 y based on biochemical results Abdominal CT or MRI Pancreatic NETs 20 Every 3–5 y based on biochemical results Abdominal CT, MRI, or endoscopic US Pancreatic NETs <10 Every 1 y